First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS

Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals

(2013) Natalie Nokoff et al.   Annals of the New York Academy of Sciences

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Prediction of Type 1 Diabetes in the General Population

(2010) M. Knip et al.   DIABETES CARE

Etiology of Type 1 Diabetes

(2010) John A. Todd   IMMUNITY

Prediction and Pathogenesis in Type 1 Diabetes

(2010) Anette-G. Ziegler et al.   IMMUNITY